SMO Clinplus Co (SZSE:301257) ROCE % : 6.99% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SMO Clinplus Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 6.99%.

SMO Clinplus Co ROCE % Historical Data

The historical data trend for SMO Clinplus Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co ROCE % Chart

SMO Clinplus Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

62.23

32.08

33.82

13.71

15.83

SMO Clinplus Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															17.89	15.81	9.59	13.45	6.99

SMO Clinplus Co ROCE % Calculation

SMO Clinplus Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	161.357	/	( ( (1160.719 - 208.433)	+	(1366.819 - 280.748) )	/ 2 )
	=	161.357	/	( (952.286	+	1086.071)	/ 2 )
	=	161.357	/	1019.1785
	=	15.83 %

SMO Clinplus Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	79.52	/	( ( (1388.561 - 254.639)	+	(1380.627 - 238.75) )	/ 2 )
	=	79.52	/	( ( 1133.922	+	1141.877 )	/ 2 )
	=	79.52	/	1137.8995
	=	6.99 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

SMO Clinplus Co (SZSE:301257) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SMO Clinplus Co ROCE % Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SMO Clinplus Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001

Website

http://www.smo-clinplus.com

SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.

Executives

Lai Chun Bao	Director
Ma Yu Ping	Supervisors
Ma Lin	Director

SMO Clinplus Co Headlines

No Headlines